Suggested remit: To appraise the clinical and cost effectiveness of Sasanlimab with BCG within its marketing authorisation for treating bladder cancer.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA® ...

These leaflets are suspended from the muscular atrioventricular junction apart from a small area of membranous septum. They are joined by papillary muscles: the medial papillary muscle between the ...

The gene therapy nadofaragene firadenovec demonstrated strong clinical activity in Japanese patients with BCG-unresponsive ...

Johnson & Johnson (NYSE: JNJ) announced today that new data from its leading oncology pipeline will be presented at the American Urological Association (AUA) 2025 Annual Meeting, taking place April 26 ...

At AUA 2025, experts will present on novel bladder cancer therapies, advanced renal cell carcinoma comparisons, frailty in ...

Ferring Pharmaceuticals announced today the U.S. Food and Drug Administration (FDA) approved a state-of-the-art drug product manufacturing hub in Parsippany, NJ, for its intravesical non-replicating ...

Results from the Phase IIb SunRISe-1 study demonstrated a one-year duration of response with the TAR-200 intravesical ...

Ferring Pharmaceuticals presented the initial results from an ongoing Phase 3 trial (NCT05704244) in Japan assessing the efficacy and safety of ADSTILADRIN® (nadofaragene firadenovec-vncg) in patients ...

for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary ...